Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor.

Brain tumors and brain metastases are among the deadliest malignancies of all human cancers, largely due to the cellular blood-brain and blood-tumor barriers that limit the delivery of imaging and therapeutic agents from the systemic circulation to tumors. Thus, improved strategies for brain tumor visualization and targeted treatment are critically needed. Here we identified and synthesized a group of near-infrared fluorescence (NIRF) heptamethine carbocyanine dyes and derivative NIRF dye-drug conjugates for effective imaging and therapeutic targeting of brain tumors of either primary or metastatic origin in mice, which is mechanistically mediated by tumor hypoxia and organic anion-transporting polypeptide genes. We also demonstrate that these dyes, when conjugated to chemotherapeutic agents such as gemcitabine, significantly restricted the growth of both intracranial glioma xenografts and prostate tumor brain metastases and prolonged survival in mice. These results show promise in the application of NIRF dyes as novel theranostic agents for the detection and treatment of brain tumors.

[1]  Theresia Thalhammer,et al.  Tumor-Specific Expression of Organic Anion-Transporting Polypeptides: Transporters as Novel Targets for Cancer Therapy , 2013, Journal of drug delivery.

[2]  A. Multani,et al.  Prostate cancer metastasis: Role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis , 2006, The Prostate.

[3]  Hsiao-Wen Chung,et al.  Advanced MR Imaging of Gliomas: An Update , 2013, BioMed research international.

[4]  W. Bezwoda,et al.  Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[6]  K. Hoang-Xuan,et al.  Primary brain tumours in adults , 2003, The Lancet.

[7]  Donghak Kim,et al.  Role of hypoxia inducible factor-1α in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer. , 2013, Biochemical pharmacology.

[8]  J. Seoane,et al.  Brain metastasis: New opportunities to tackle therapeutic resistance , 2014, Molecular oncology.

[9]  R. Jensen,et al.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target , 2009, Journal of Neuro-Oncology.

[10]  Jesse V. Jokerst,et al.  A Brain Tumor Molecular Imaging Strategy Using A New Triple-Modality MRI-Photoacoustic-Raman Nanoparticle , 2011, Nature Medicine.

[11]  H. Kusuhara,et al.  Functional Characterization of Mouse Organic Anion Transporting Peptide 1a4 in the Uptake and Efflux of Drugs Across the Blood-Brain Barrier , 2010, Drug Metabolism and Disposition.

[12]  M. Hiraoka,et al.  The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. , 2007, Biochemical and biophysical research communications.

[13]  Takashi Tsukamoto,et al.  High-affinity Near-infrared Fluorescent Small-molecule Contrast Agents for In Vivo Imaging of Prostate-specific Membrane Antigen , 2005, Molecular imaging.

[14]  Chun-Peng Liao,et al.  Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. , 2014, The Journal of clinical investigation.

[15]  B. Zhang,et al.  LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. , 2013, Biomaterials.

[16]  Sagar Agarwal,et al.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain , 2011, Expert Reviews in Molecular Medicine.

[17]  V. Subramaniam,et al.  Cyanine dye-protein interactions: looking for fluorescent probes for amyloid structures. , 2007, Journal of biochemical and biophysical methods.

[18]  H. Ihmels,et al.  Light up G-quadruplex DNA with a [2.2.2]heptamethinecyanine dye. , 2013, Organic & biomolecular chemistry.

[19]  A. Osunkoya,et al.  Optical imaging of kidney cancer with novel near infrared heptamethine carbocyanine fluorescent dyes. , 2013, The Journal of urology.

[20]  M. Vogelbaum,et al.  Function of the Blood-Brain Barrier and Restriction of Drug Delivery to Invasive Glioma Cells: Findings in an Orthotopic Rat Xenograft Model of Glioma , 2013, Drug Metabolism and Disposition.

[21]  Qiang Zhang,et al.  Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  L. Strekowski,,et al.  Imaging , Diagnosis , Prognosis Clinical Cancer Research Near IR Heptamethine Cyanine Dye – Mediated Cancer Imaging , 2010 .

[23]  Melissa Bondy,et al.  Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.

[24]  Mark Muzi,et al.  Positron emission tomography imaging of brain tumors. , 2003, Neuroimaging clinics of North America.

[25]  Quanyin Hu,et al.  The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. , 2013, Biomaterials.

[26]  K. Black,et al.  Isolation of tumour stem-like cells from benign tumours , 2009, British Journal of Cancer.

[27]  B. Hagenbuch,et al.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies , 2012, British journal of pharmacology.

[28]  Bruno Hagenbuch,et al.  The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. , 2012, Annual review of pharmacology and toxicology.

[29]  P. Wen,et al.  Antiangiogenic therapies for high-grade glioma , 2009, Nature Reviews Neurology.

[30]  Susan M. Chang,et al.  Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. , 2005, Journal of neurosurgery.

[31]  Michael D. Henry,et al.  Assessing Tumor Growth and Distribution in a Model of Prostate Cancer Metastasis using Bioluminescence Imaging , 2006, Clinical & Experimental Metastasis.

[32]  Markus Rudin,et al.  In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe , 2005, Nature Biotechnology.

[33]  L. Hertel,et al.  Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.

[34]  Jayant P. Menon,et al.  Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.

[35]  Adam de la Zerda,et al.  A Comparison Between Time Domain and Spectral Imaging Systems for Imaging Quantum Dots in Small Living Animals , 2010, Molecular Imaging and Biology.

[36]  Dongfeng Pan,et al.  Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer , 2013, Translational andrology and urology.

[37]  P. Ronaldson,et al.  Hypoxia/Reoxygenation Stress Signals an Increase in Organic Anion Transporting polypeptide 1a4 (Oatp1a4) at the Blood–Brain Barrier: Relevance to CNS Drug Delivery , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  L. Chung,et al.  Heptamethine carbocyanine dye-mediated near-infrared imaging of canine and human cancers through the HIF-1α/OATPs signaling axis , 2014, Oncotarget.

[39]  D. Groothuis,et al.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. , 2000, Neuro-oncology.

[40]  Xin Lu,et al.  Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis , 2010, Clinical Cancer Research.

[41]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[42]  Wei Li,et al.  Near-infrared fluorescence imaging of cancer mediated by tumor hypoxia and HIF1α/OATPs signaling axis. , 2014, Biomaterials.

[43]  Veit Rohde,et al.  Multiphoton excitation fluorescence microscopy of 5‐aminolevulinic acid induced fluorescence in experimental gliomas , 2008, Lasers in surgery and medicine.

[44]  D. Schadendorf,et al.  Brain metastasis: opportunity for drug development? , 2012, Current opinion in neurology.

[45]  M. Bruchez,et al.  Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots , 2003, Nature Biotechnology.

[46]  A. Olivi,et al.  Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience , 2007, Journal of Neuro-Oncology.

[47]  J. Benoit,et al.  Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. , 2009, Biomaterials.

[48]  E M Sevick-Muraca,et al.  Translation of near-infrared fluorescence imaging technologies: emerging clinical applications. , 2012, Annual review of medicine.

[49]  G. Peters,et al.  Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  S. Ostad,et al.  Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: a comparison with its self-assembled nanoparticles. , 2014, International journal of pharmaceutics.

[51]  Dejan Juric,et al.  Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. , 2005, Cancer research.

[52]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Shih,et al.  Monoamine oxidase A inhibitor-near-infrared dye conjugate reduces prostate tumor growth. , 2015, Journal of the American Chemical Society.

[54]  A. Harris,et al.  Advanced breast cancer: a phase II trial with gemcitabine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Ghosh,et al.  Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors , 2015, BioMed research international.

[56]  D. Keppler,et al.  ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. , 2005, Cancer research.

[57]  Mark Voorneveld,et al.  Preparation , 2018, Games Econ. Behav..

[58]  Peter Vajkoczy,et al.  Vascular microenvironment in gliomas. , 2004, Cancer treatment and research.

[59]  J. Koenderink.  Q… , 2014, Les noms officiels des communes de Wallonie, de Bruxelles-Capitale et de la communaute germanophone.

[60]  D. Shewach,et al.  The role of DNA synthesis inhibition in the cytotoxicity of 2′,2′-difluoro-2′-deoxycytidine , 2003, Cancer Chemotherapy and Pharmacology.